Free Trial

Sage Therapeutics (SAGE) Competitors

+0.03 (+0.26%)
(As of 07/12/2024 ET)


Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Emergent BioSolutions (EBS), Schrödinger (SDGR), Morphic (MORF), Geron (GERN), Bausch Health Companies (BHC), Agios Pharmaceuticals (AGIO), PTC Therapeutics (PTCT), Amneal Pharmaceuticals (AMRX), Maravai LifeSciences (MRVI), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.

Sage Therapeutics vs.

Emergent BioSolutions (NYSE:EBS) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.

Sage Therapeutics received 214 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. Likewise, 67.31% of users gave Sage Therapeutics an outperform vote while only 66.56% of users gave Emergent BioSolutions an outperform vote.

Emergent BioSolutionsOutperform Votes
Underperform Votes
Sage TherapeuticsOutperform Votes
Underperform Votes

Emergent BioSolutions has a net margin of -47.68% compared to Emergent BioSolutions' net margin of -552.52%. Sage Therapeutics' return on equity of -18.53% beat Emergent BioSolutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Emergent BioSolutions-47.68% -18.53% -7.14%
Sage Therapeutics -552.52%-56.81%-51.01%

Emergent BioSolutions currently has a consensus price target of $8.00, indicating a potential downside of 24.88%. Sage Therapeutics has a consensus price target of $34.55, indicating a potential upside of 193.79%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, analysts plainly believe Sage Therapeutics is more favorable than Emergent BioSolutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emergent BioSolutions
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
Sage Therapeutics
2 Sell rating(s)
15 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)

In the previous week, Emergent BioSolutions and Emergent BioSolutions both had 6 articles in the media. Emergent BioSolutions' average media sentiment score of 0.45 beat Sage Therapeutics' score of 0.20 indicating that Sage Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Emergent BioSolutions
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Sage Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

78.4% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 1.2% of Emergent BioSolutions shares are held by insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Emergent BioSolutions has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

Sage Therapeutics has lower revenue, but higher earnings than Emergent BioSolutions. Sage Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.05B0.53-$760.50M-$11.01-0.97
Sage Therapeutics$91.06M7.77-$541.49M-$8.40-1.40


Sage Therapeutics beats Emergent BioSolutions on 11 of the 17 factors compared between the two stocks.

Get Sage Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SAGE vs. The Competition

MetricSage TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$707.74M$7.31B$5.40B$8.73B
Dividend YieldN/A2.73%2.77%4.04%
P/E Ratio-1.4012.42112.0315.99
Price / Sales7.77315.872,182.0883.83
Price / CashN/A33.2136.4333.15
Price / Book0.885.844.944.46
Net Income-$541.49M$146.83M$111.51M$215.59M
7 Day Performance9.09%10.49%6.20%5.35%
1 Month Performance-2.00%6.45%5.71%4.39%
1 Year Performance-74.76%0.03%6.49%1.77%

Sage Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Emergent BioSolutions
3.1231 of 5 stars
3.12 / 5 stars
+46.3%$539.20M$1.05B-0.931,600Short Interest ↓
News Coverage
2.2043 of 5 stars
2.20 / 5 stars
-58.5%$1.62B$216.67M-11.88867Analyst Forecast
News Coverage
3.3492 of 5 stars
3.35 / 5 stars
-4.5%$2.79B$520,000.00-15.93121Analyst Forecast
Insider Selling
News Coverage
High Trading Volume
4.2059 of 5 stars
4.21 / 5 stars
+46.7%$2.78B$240,000.00-13.4070Insider Selling
Short Interest ↓
News Coverage
Bausch Health Companies
3.9981 of 5 stars
4.00 / 5 stars
-11.7%$2.70B$8.76B-6.0220,270Analyst Forecast
News Coverage
Agios Pharmaceuticals
3.1259 of 5 stars
3.13 / 5 stars
+64.1%$2.58B$26.82M-7.20383Analyst Upgrade
Short Interest ↓
News Coverage
Positive News
PTC Therapeutics
3.862 of 5 stars
3.86 / 5 stars
-16.4%$2.54B$937.82M-4.31988Analyst Forecast
Short Interest ↓
News Coverage
Amneal Pharmaceuticals
1.1607 of 5 stars
1.16 / 5 stars
+136.1%$2.25B$2.39B-13.027,700Short Interest ↑
News Coverage
Maravai LifeSciences
3.7884 of 5 stars
3.79 / 5 stars
-30.4%$2.24B$288.95M-8.99650Analyst Forecast
Options Volume
News Coverage
Janux Therapeutics
3.1055 of 5 stars
3.11 / 5 stars
+251.6%$2.22B$8.08M-35.1168Short Interest ↑

Related Companies and Tools

This page (NASDAQ:SAGE) was last updated on 7/14/2024 by Staff

From Our Partners